508 related articles for article (PubMed ID: 23013350)
1. A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat.
Singh N; Sharma G; Singh N; Hanif K
Int J Stroke; 2014 Jul; 9(5):560-8. PubMed ID: 23013350
[TBL] [Abstract][Full Text] [Related]
2. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Engelhorn T; Doerfler A; Heusch G; Schulz R
Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effect of combination of poly (ADP-ribose) polymerase inhibitor and antioxidant in middle cerebral artery occlusion induced focal ischemia in rats.
Gupta S; Kaul CL; Sharma SS
Neurol Res; 2004 Jan; 26(1):103-7. PubMed ID: 14977067
[TBL] [Abstract][Full Text] [Related]
4. Long-term neuroprotective effect of inhibiting poly(ADP-ribose) polymerase in rats with middle cerebral artery occlusion using a behavioral assessment.
Ding Y; Zhou Y; Lai Q; Li J; Gordon V; Diaz FG
Brain Res; 2001 Oct; 915(2):210-7. PubMed ID: 11595210
[TBL] [Abstract][Full Text] [Related]
5. Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.
Brdon J; Kaiser S; Hagemann F; Zhao Y; Culman J; Gohlke P
J Hypertens; 2007 Jan; 25(1):187-96. PubMed ID: 17143191
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase.
Moroni F; Cozzi A; Chiarugi A; Formentini L; Camaioni E; Pellegrini-Giampietro DE; Chen Y; Liang S; Zaleska MM; Gonzales C; Wood A; Pellicciari R
Br J Pharmacol; 2012 Mar; 165(5):1487-500. PubMed ID: 21913897
[TBL] [Abstract][Full Text] [Related]
7. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats.
Groth W; Blume A; Gohlke P; Unger T; Culman J
J Hypertens; 2003 Nov; 21(11):2175-82. PubMed ID: 14597862
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
Fu H; Hosomi N; Pelisch N; Nakano D; Liu G; Ueno M; Miki T; Masugata H; Sueda Y; Itano T; Matsumoto M; Nishiyama A; Kohno M
J Hypertens; 2011 Nov; 29(11):2210-9. PubMed ID: 21934531
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effect of peroxynitrite decomposition catalyst and poly(adenosine diphosphate-ribose) polymerase inhibitor alone and in combination in rats with focal cerebral ischemia.
Sharma SS; Munusamy S; Thiyagarajan M; Kaul CL
J Neurosurg; 2004 Oct; 101(4):669-75. PubMed ID: 15481724
[TBL] [Abstract][Full Text] [Related]
10. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
[TBL] [Abstract][Full Text] [Related]
11. A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats.
Nakajima H; Kakui N; Ohkuma K; Ishikawa M; Hasegawa T
J Pharmacol Exp Ther; 2005 Feb; 312(2):472-81. PubMed ID: 15466246
[TBL] [Abstract][Full Text] [Related]
12. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model.
Ikeda Y; Hokamura K; Kawai T; Ishiyama J; Ishikawa K; Anraku T; Uno T; Umemura K
Brain Res; 2005 Oct; 1060(1-2):73-80. PubMed ID: 16202986
[TBL] [Abstract][Full Text] [Related]
14. Neuropilin-1 modulates vascular endothelial growth factor-induced poly(ADP-ribose)-polymerase leading to reduced cerebrovascular apoptosis.
Mey L; Hörmann M; Schleicher N; Reuter P; Dönges S; Kinscherf R; Gassmann M; Gerriets T; Al-Fakhri N
Neurobiol Dis; 2013 Nov; 59():111-25. PubMed ID: 23816753
[TBL] [Abstract][Full Text] [Related]
15. Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat.
Lou M; Blume A; Zhao Y; Gohlke P; Deuschl G; Herdegen T; Culman J
J Cereb Blood Flow Metab; 2004 May; 24(5):536-47. PubMed ID: 15129186
[TBL] [Abstract][Full Text] [Related]
16. Cooperative effect of angiotensin AT(1) and endothelin ET(A) receptor antagonism limits the brain damage after ischemic stroke in rat.
Stenman E; Jamali R; Henriksson M; Maddahi A; Edvinsson L
Eur J Pharmacol; 2007 Sep; 570(1-3):142-8. PubMed ID: 17597600
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Culman J; Jacob T; Schuster SO; Brolund-Spaether K; Brolund L; Cascorbi I; Zhao Y; Gohlke P
Naunyn Schmiedebergs Arch Pharmacol; 2017 Sep; 390(9):949-959. PubMed ID: 28669009
[TBL] [Abstract][Full Text] [Related]
18. Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress.
Hamai M; Iwai M; Ide A; Tomochika H; Tomono Y; Mogi M; Horiuchi M
Neuropharmacology; 2006 Sep; 51(4):822-8. PubMed ID: 16824557
[TBL] [Abstract][Full Text] [Related]
19. Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.
Omura-Matsuoka E; Yagita Y; Sasaki T; Terasaki Y; Oyama N; Sugiyama Y; Okazaki S; Sakoda S; Kitagawa K
Hypertens Res; 2009 Jul; 32(7):548-53. PubMed ID: 19424281
[TBL] [Abstract][Full Text] [Related]
20. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats.
Engelhorn T; Goerike S; Doerfler A; Okorn C; Forsting M; Heusch G; Schulz R
J Cereb Blood Flow Metab; 2004 Apr; 24(4):467-74. PubMed ID: 15087716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
